Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Disitamab Vedotin + Chemotherapy ± PD-1 in HER2-low Gastric/GEJ Adenocarcinoma
ChiCTR2500112528Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of disitamab vedotin in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Tumor Regression Grade 0/1 (TRG 0/1). Planned start Nov 2025; status: not yet recruiting.
02
Drugs
disitamab vedotin
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500112528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112528.